Ai Yan-Ling, Tang Jian-Yuan, Zhou Gang, Zhang Lei, Qu Li-Ping, Huang Shi-Yao, Yang Zhong-Qi, Yuan Wei-An, Zhou Yue-Hua, Wang Ting, Zhao Jun-Ning, Sun Xiao-Bo, Xiao Xiao-He, Yang Zi-Feng, Liu Qing-Quan, Zhu Ming-Jun, Leng Xiang-Yang, Xie Chun-Guang, Chai Song-Yan
Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 610075, China.
Center for Drug Evaluation,National Medical Products Administration Beijing 100022, China.
Zhongguo Zhong Yao Za Zhi. 2022 Feb;47(4):1120-1125. doi: 10.19540/j.cnki.cjcmm.20211027.501.
Since the implementation of drug registration in China, the classification of Chinese medicine has greatly met the needs of public health and effectively guided the transformation, inheritance, and innovation of research achievements on traditional Chinese medicine(TCM). In the past 30 years, the development of new Chinese medicine has followed the registration transformation model of " one prescription for single drug". This model refers to the R&D and registration system of modern drugs, and approximates to the " law-abiding" medication method in TCM clinic, while it rarely reflects the sequential therapy of syndrome differentiation and comprehensive treatment with multiple measures. In 2017, Opinions on Deepening the Reform of Review and Approval System and Encouraging the Innovation of Drugs and Medical Devices released by the General Office of the CPC Central Committee and the General Office of the State Council pointed out that it is necessary to " establish and improve the registration and technical evaluation system in line with the characteristics of Chinese medicine, and handle the relationship between the traditional advantages of Chinese medicine and the requirements of modern drug research". Therefore, based on the development law and characteristics of TCM, clinical thinking should be highlighted in the current technical requirements and registration system of research and development of Chinese medicine. Based on the current situation of registration supervision of Chinese medicine and the modern drug research in China, the present study analyzed limitations and deficiency of " one prescription for single drug" in the research and development of Chinese medicine. Additionally, a new type of " series prescriptions" was proposed, which was consistent with clinical thinking and clinical reality. This study is expected to contribute to the independent innovation and high-quality development of the TCM industry.
自我国实施药品注册以来,中药分类极大地满足了公共卫生需求,并有效引导了中医药研究成果的转化、传承与创新。在过去30年里,中药新药的研发遵循“一药一方”的注册转化模式。这种模式参照现代药物的研发和注册体系,近似于中医临床的“守法”用药方式,但很少体现辨证论治、多法联用的序贯治疗。2017年,中共中央办公厅、国务院办公厅印发的《关于深化审评审批制度改革鼓励药品医疗器械创新的意见》指出,要“建立健全符合中医药特点的注册审评技术体系,处理好中医药传统优势与现代药品研发要求的关系”。因此,应基于中医药的发展规律和特点,在当前中药研发的技术要求和注册体系中突出临床思维。本研究基于我国中药注册监管现状及现代药物研究情况,分析了“一药一方”在中药研发中的局限与不足。此外,提出了一种符合临床思维和临床实际的新型“系列方”。本研究有望为中医药产业的自主创新和高质量发展提供助力。